Cancer Discov. 2020 Jul;10(7):OF7. doi: 10.1158/2159-8290.CD-ND2020-010. Epub 2020 May 28.
Circulating tumor DNA (ctDNA) may be a useful biomarker for minimal residual disease (MRD) in patients with early-stage non-small cell lung cancer-and MRD may be a good predictor of relapse. In the TRACERx study, a ctDNA assay confirmed MRD negativity in more than 99% of patients-and detected MRD in patients who relapsed before their disease was picked up by standard imaging.
循环肿瘤 DNA（ctDNA）可能是早期非小细胞肺癌患者微小残留病灶（MRD）的有用生物标志物——而 MRD 可能是复发的良好预测指标。在 TRACERx 研究中，ctDNA 检测方法证实了超过 99%的患者的 MRD 阴性，并在疾病标准影像学检测前就检测到了复发患者的 MRD。
